Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BWVNASDAQ:ENSCNASDAQ:KLDONASDAQ:MNPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBWVOnconetix$77.50$0.18$0.18▼$1.95$1.45B3.58795,235 shs1,999 shsENSCEnsysce Biosciences$2.26-5.0%$2.41$1.62▼$14.67$5.36M1.09927,962 shs49,552 shsKLDOKaleido Biosciences$0.00$0.00$0.00▼$0.07$9K-0.068,049 shsN/AMNPRMonopar Therapeutics$32.46-7.9%$37.52$1.72▼$54.30$198.49M1.11359,566 shs31,538 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBWVOnconetix0.00%0.00%0.00%+42,907.77%+42,907.77%ENSCEnsysce Biosciences-5.04%+1.35%-22.87%-56.95%-73.80%KLDOKaleido Biosciences0.00%0.00%-98.00%+100.00%+100.00%MNPRMonopar Therapeutics-7.91%-8.72%-20.46%+7.31%+947.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBWVOnconetixN/AN/AN/AN/AN/AN/AN/AN/AENSCEnsysce Biosciences0.1947 of 5 stars0.02.00.00.03.30.00.0KLDOKaleido BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AMNPRMonopar Therapeutics2.9496 of 5 stars3.45.00.00.03.02.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBWVOnconetix 0.00N/AN/AN/AENSCEnsysce Biosciences 0.00N/AN/AN/AKLDOKaleido Biosciences 0.00N/AN/AN/AMNPRMonopar Therapeutics 2.75Moderate Buy$55.3370.47% UpsideCurrent Analyst Ratings BreakdownLatest MNPR, KLDO, BWV, and ENSC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025MNPRMonopar TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/1/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/19/2025MNPRMonopar TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$76.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBWVOnconetixN/AN/AN/AN/A$1.63 per shareN/AENSCEnsysce Biosciences$2.23M2.40N/AN/A($3.10) per share-0.73KLDOKaleido Biosciences$1.10M0.01N/AN/AN/A∞MNPRMonopar TherapeuticsN/AN/AN/AN/A$1.88 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBWVOnconetix-$13.42M-$1.08N/A∞N/AN/A-108.19%-66.47%N/AENSCEnsysce Biosciences-$10.61M-$6.54N/AN/AN/A-179.26%-292.81%-158.83%8/13/2025 (Estimated)KLDOKaleido BiosciencesN/A-$2.24N/AN/AN/AN/AN/AN/AN/AMNPRMonopar Therapeutics-$8.40M-$3.48N/AN/AN/AN/A-107.21%-87.57%8/8/2025 (Estimated)Latest MNPR, KLDO, BWV, and ENSC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ENSCEnsysce Biosciences-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 million5/13/2025Q1 2025MNPRMonopar Therapeutics-$0.65-$0.38+$0.27-$0.38N/AN/A3/31/2025Q4 2024MNPRMonopar Therapeutics-$0.36-$2.23-$1.87-$2.23N/AN/A3/10/2025Q4 2024ENSCEnsysce Biosciences-$2.74-$2.90-$0.16-$2.90$0.25 million$1.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBWVOnconetixN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBWVOnconetixN/A0.540.46ENSCEnsysce BiosciencesN/A3.243.24KLDOKaleido BiosciencesN/AN/AN/AMNPRMonopar TherapeuticsN/A5.415.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBWVOnconetix22.34%ENSCEnsysce Biosciences5.63%KLDOKaleido Biosciences81.56%MNPRMonopar Therapeutics1.83%Insider OwnershipCompanyInsider OwnershipBWVOnconetix19.50%ENSCEnsysce Biosciences7.90%KLDOKaleido Biosciences9.00%MNPRMonopar Therapeutics20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBWVOnconetix1218.66 million15.02 millionNot OptionableENSCEnsysce Biosciences102.37 million1.20 millionNot OptionableKLDOKaleido Biosciences8042.62 million38.79 millionNot OptionableMNPRMonopar Therapeutics106.12 million3.97 millionNot OptionableMNPR, KLDO, BWV, and ENSC HeadlinesRecent News About These CompaniesMonopar Therapeutics (NASDAQ:MNPR) Stock Rating Upgraded by Wall Street ZenMay 24, 2025 | marketbeat.comPoint72 Asset Management L.P. Takes Position in Monopar Therapeutics Inc. (NASDAQ:MNPR)May 23, 2025 | marketbeat.comJanus Henderson Group PLC Invests $23.44 Million in Monopar Therapeutics Inc. (NASDAQ:MNPR)May 18, 2025 | marketbeat.comMonopar Therapeutics Reports First Quarter 2025 Financial Results and Recent DevelopmentsMay 14, 2025 | manilatimes.netMonopar Therapeutics Reports First Quarter 2025 Financial Results and Recent DevelopmentsMay 13, 2025 | globenewswire.comMonopar Therapeutics Presents Long-Term Efficacy and Safety Data for ALXN1840 in Wilson Disease at EASL International Liver Congress 2025May 8, 2025 | nasdaq.comMonopar Presents ALXN1840 Late-Breaker Data at EASL 2025May 7, 2025 | globenewswire.comGeode Capital Management LLC Acquires 24,530 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR)May 4, 2025 | marketbeat.comRA Capital Management L.P. Invests $11.25 Million in Monopar Therapeutics Inc. (NASDAQ:MNPR)May 3, 2025 | marketbeat.comMonopar Therapeutics (MNPR) Projected to Post Earnings on ThursdayMay 3, 2025 | marketbeat.comWhy Monopar Therapeutics Inc. (MNPR) is Surging in 2025April 30, 2025 | insidermonkey.comAdage Capital Partners GP L.L.C. Takes Position in Monopar Therapeutics Inc. (NASDAQ:MNPR)April 30, 2025 | marketbeat.comMonopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025April 29, 2025 | globenewswire.comPiper Sandler Remains a Buy on Monopar Therapeutics Inc (MNPR)April 14, 2025 | markets.businessinsider.comWhy Monopar Therapeutics Inc.’s (MNPR) Stock Is Down 9.91%April 10, 2025 | aaii.comWhy Monopar Therapeutics Inc.’s (MNPR) Stock Is Down 13.27%April 5, 2025 | aaii.comTactic Pharma Llc Sells 33,334 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) StockApril 5, 2025 | insidertrades.comMonopar Therapeutics downgraded to Hold from Buy at JonesResearchApril 2, 2025 | markets.businessinsider.comJones Trading Downgrades Monopar Therapeutics (MNPR)April 2, 2025 | msn.comJonesTrading downgrades Monopar Therapeutics Inc (MNPR) to a HoldApril 2, 2025 | markets.businessinsider.comWe Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business GrowthApril 2, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNPR, KLDO, BWV, and ENSC Company DescriptionsOnconetix NASDAQ:BWVBlue Water Biotech, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Vaccines, Inc. and changed its name to Blue Water Biotech, Inc. in April 2023. Blue Water Biotech, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.Ensysce Biosciences NASDAQ:ENSC$2.26 -0.12 (-5.04%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$2.23 -0.03 (-1.28%) As of 05/28/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.Kaleido Biosciences NASDAQ:KLDO$0.0002 0.00 (0.00%) As of 05/27/2025Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Monopar Therapeutics NASDAQ:MNPR$32.46 -2.79 (-7.91%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$34.50 +2.04 (+6.28%) As of 05/28/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
